LGND · Ligand Pharmaceuticals Inc
United States · RS rating 92 · As of 2026-10-14
| Price | 294.99 USD |
|---|---|
| 1-day change | -2.8% |
| RS rating (overall / 1M / 3M / 12M) | 92 / 91 / 62 / 92 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 47 / 54 / 49 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -62.7% |
| Sales growth Q/Q | -48.3% |
| Distance from 52-week high | +8.6% |
| Market cap (USD) | $4.6B |